In order to strengthen its neuroscience pipeline, Lundbeck has agreed to acquire Longboard Pharmaceuticals for a total transaction value of approximately US$2.6 B. Through the deal, Lundbeck picks up access to Longboard’s lead asset bexicaserin in late-stage development for the treatment of developmental and epileptic encephalopathies (DEEs), including Dravet syndrome, Lennox-Gastaut syndrome, and other rare epilepsies. The acquisition will enhance and complement Lundbeck’s existing neuro-rare disease portfolio, as it prepares to face upcoming patent expiries for several of its key assets including Trintellix and Rexulti.